Related Experiment Video
Updated: Aug 11, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer
Chen Zhang1, Xiyi Lu1, Xinyin Liu1
1Jiangsu Province Hospital and Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu, China.
Abstract:
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI, such as gefitinib) in lung cancer continues to be a major problem. Recent studies have shown the promise of ferroptosis-inducing therapy in EGFR-TKI resistant cancer, but have not been translated into clinical benefits. Here, we identified carbonic anhydrase IX (CA9) was upregulated in gefitinib-resistant lung cancer. Then we measured the cell viability, intracellular reactive oxygen species (ROS) levels, and labile iron levels after the treatment of ferroptosis inducer erastin. We found that CA9 confers resistance to ferroptosis-inducing drugs. Mechanistically, CA9 is involved in the inhibition of transferrin endocytosis and the stabilization of ferritin, leading to resistance to ferroptosis. Targeting CA9 promotes iron uptake and release, thus triggering gefitinib-resistant cell ferroptosis. Notably, CA9 inhibitor enhances the ferroptosis-inducing effect of cisplatin on gefitinib-resistant cells, thus eliminating resistant cells in heterogeneous tumor tissues. Taken together, CA9-targeting therapy is a promising approach to improve the therapeutic effect of gefitinib-resistant lung cancer by inducing ferroptosis.
Insights
Carbonic anhydrase IX (CA9) drives resistance to EGFR-TKI therapy in lung cancer by blocking ferroptosis. Targeting CA9 restores ferroptosis, offering a new strategy to overcome gefitinib resistance.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) is a significant challenge in lung cancer treatment.
- Ferroptosis-inducing therapy shows potential against EGFR-TKI resistant cancers but lacks clinical translation.
Purpose of the Study:
- To investigate the role of carbonic anhydrase IX (CA9) in gefitinib-resistant lung cancer.
- To explore CA9 as a therapeutic target to overcome resistance by inducing ferroptosis.
Main Methods:
- Upregulation of CA9 in gefitinib-resistant lung cancer cells was identified.
- Cell viability, reactive oxygen species (ROS), and labile iron levels were measured after erastin treatment.
- Mechanisms of CA9-mediated ferroptosis resistance were investigated, including transferrin endocytosis and ferritin stabilization.
Main Results:
- CA9 was found to confer resistance to ferroptosis-inducing drugs by inhibiting transferrin endocytosis and stabilizing ferritin.
- Targeting CA9 promoted iron uptake and release, inducing ferroptosis in gefitinib-resistant cells.
- A CA9 inhibitor enhanced cisplatin's ferroptosis-inducing effect, leading to the elimination of resistant cells in heterogeneous tumors.
Conclusions:
- CA9 plays a critical role in mediating resistance to ferroptosis in lung cancer.
- Targeting CA9 is a promising therapeutic strategy to enhance the efficacy of gefitinib and overcome treatment resistance by inducing ferroptosis.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Regulation of Angiogenesis and Blood Supply
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Aquaporins